Publications

DSUVIA^®

1. Primary Manuscript for SAP301

Minkowitz HS, Leiman D, Melson T, Singla N, Didonato KP, Palmer PP. Sufentanil sublingual tablet 30 mcg for the management of pain following abdominal surgery: a randomized, placebo-controlled, phase 3 study. Pain Pract. 2017;17(7):848-858.

http://onlinelibrary.wiley.com/doi/10.1111/papr.12531/abstract

2. Primary Manuscript for SAP302 (open-label study)

Miner JR, Rafique Z, Minkowitz HS, DiDonato KP, Palmer PP. Sufentanil sublingual tablet 30 mcg for moderate-to-severe acute pain in the ED. Am J Emerg Med. 2018;36(6):954-961.

https://www.sciencedirect.com/science/article/pii/S0735675717308860

3. Primary Manuscript for SAP303 (open-label study)

Hutchins JL, Leiman D, Minkowitz HS, Jove M, DiDonato KP, Palmer PP. An open-label study of sufentanil sublingual tablet 30 mcg in patients with postoperative pain. Pain Med. 2018;19(10):2058-2068.

https://academic.oup.com/painmedicine/article/19/10/2058/4590264

4. DSUVIA PK Manuscript

Fisher DM, Chang P, Wada R, Dahan A, Palmer PP. Pharmacokinetic properties of a sufentanil sublingual tablet intended to treat acute pain. Anesthesiology. 2018;128(5):943-952.

http://anesthesiology.pubs.asahq.org/article.aspx?articleid=2674298

5. Miner Safety Review Manuscript

Miner J. Pooled Phase III safety analysis of sufentanil sublingual tablets for short-term treatment of moderate-to-severe acute pain. J Pain Management. 2019 epub ahead of print.

https://www.futuremedicine.com/doi/10.2217/pmt-2018-0090

6. DSUVIA: A Pooled Dosing and Efficacy Analysis Across Demographic Subgroups

Hutchins JL, Leiman D, Rafique Z, DiDonato KP, Palmer PP. Pooled dosing and efficacy analysis of the sufentanil sublingual tablet 30 mcg across demographic subgroups for the management of moderate-to-severe acute pain. J Perianesth Nurs. 2020;35(1):22-28.

https://www.sciencedirect.com/science/article/pii/S1089947219303491

7. DSUVIA Real-World Study: Ambulatory Surgery Setting

Tvetenstrand CD, Wolff ME. Reduced opioid use and reduced time in the postanesthesia care unit following preoperative administration of sublingual sufentanil in an ambulatory surgery setting. J Clin Anesth Pain Manag. 2020;4(2):123-128.

https://scholars.direct/Articles/anesthesia-and-pain-management/jcapm-4-027.php…

8. DSUVIA Real-World Study: Perioperative Pain Management

Cassavaugh KM, Hogan SM, Senska JC, Cady MD. A medication use evaluation of sufentanil sublingual tablet 30 mcg for the perioperative management of surgical pain. J Univ Surg. 2020;8(5):6.

https://www.jusurgery.com/universalsurgery/a-medication-use-evaluation-of-sufen…

9. DSUVIA: A Pooled Demographic Analysis of Satisfaction and Safety

Leiman D, Jové M, Spahn GR, Palmer P. Patient and healthcare professional satisfaction ratings and safety profile of sufentanil sublingual tablets for treatment of acute pain: a pooled demographic analysis. J Pain Res. 2021;14:805-813.

https://www.dovepress.com/patient-and-healthcare-professional-satisfaction-rati…

10. DSUVIA Real-World Study: Total Hip and Total Knee Arthroplasties

Wiesner L, Tvetenstrand, C. Reduced Opioid Use and Hospital Stay in Patients Undergoing Total Knee or Total Hip Arthroplasty When Treated with Sublingual Sufentanil Compared with Standard of Analgesic Care. J Orth Exp & Inn. 2021.

https://journaloei.scholasticahq.com/article/29105-reduced-opioid-use-and-hospi…

11. DSUVIA Use in the Military

Kim S, Buckenmaier C, Howe E, Choi K. The Newest Battlefield Opioid, Sublingual Sufentanil: A Proposal to Refine Opioid Usage in the U.S. Military. Mil Med. 2021, 9.

https://academic.oup.com/milmed/advance-article/doi/10.1093/milmed/usab395/6377…

12. DSUVIA Editorial

Sigman, S. Opioid Stewardship: Is there a “Better” Opioid? J Orth Exp & Inn. 2022, 1.

https://journaloei.scholasticahq.com/article/30092-opioid-stewardship-is-there-…

13. DSUVIA Real-World Study: Awake Plastic Surgery Procedures

Seify H. Awake Plastic Surgery Procedures: The Use of a Sufentanil Sublingual Tablet to Improve Patient Experience. Aesth Surg J Open Forum. 2022;4

https://academic.oup.com/asjopenforum/article/doi/10.1093/asjof/ojab056/6516002…

14. DSUVIA Use in Interventional Pain Procedures

Koushik S, Schwartz R, Cherkalin D, Sankar V, Shaparin N, Viswanath O. A Review of Sublingual Sufentanil Tablet and its Utility as an Analgesic Agent for Pain Procedures. Current Pain and Headache Reports. 2022;26:145-149

https://link.springer.com/article/10.1007/s11916-022-01014-0

15. DSUVIA Real-World Study: Radiofrequency Microneedling Procedures

Maningas T, Ramirez H, Martin, K. Novel Sublingual Analgesic Improves Patient Tolerance of Face and Body Radiofrequency Microneedling: A Split Face/Abdomen Study. Am J Cos Surg. 2022,4.

https://journals.sagepub.com/doi/figure/10.1177/07488068221090080

ZALVISO^®

ZALVISO is an investigational drug. It is not approved by the FDA. AcelRx makes no claims regarding the safety or effectiveness of ZALVISO.

1. ZALVISO PK Manuscript

Willsie SK, Evashenk MA, Hamel LG, Hwang SS, Chiang YK, Palmer PP. Pharmacokinetic properties of single- and repeated-dose sufentanil sublingual tablets in healthy volunteers. Clin Ther. 2015;37(1):145-155.

http://www.clinicaltherapeutics.com/article/S0149-2918(14)00733-4/abstract

2. Primary Manuscript for Phase 3 ZALVISO study IAP309

Melson TI, Boyer DL, Minkowitz HS, Turan A, Chiang YK, Evashenk MA, Palmer PP. Sufentanil sublingual tablet system vs. intravenous patient-controlled analgesia with morphine for postoperative pain control: a randomized, active-comparator trial. Pain Pract. 2014;14(8):679-688.

https://www.ncbi.nlm.nih.gov/pubmed/25155134

3. Primary Manuscript for Phase 3 ZALVISO study IAP310

Ringold FG, Minkowitz HS, Gan TJ, et al. Sufentanil sublingual tablet system for the management of postoperative pain following open abdominal surgery: a randomized, placebo-controlled study. Reg Anesth Pain Med. 2015;40(1):22-30.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4272222/

4. Primary Manuscript for Phase 3 ZALVISO study IAP311

Jove M, Griffin DW, Minkowitz HS, Ben-David B, Evashenk MA, Palmer PP. Sufentanil sublingual tablet system for the management of postoperative pain after knee or hip arthroplasty: a randomized, placebo-controlled study. Anesthesiol. 2015;123(2):434-443.

http://anesthesiology.pubs.asahq.org/article.aspx?articleid=2343031

Health Economics and Outcomes Research Articles

1. HEOR Study – Cost of IV Analgesia in the Emergency Department

Palmer PP, Walker JA, Patanwala AE, Hagberg CA, House JA. Cost of intravenous analgesia for the management of acute pain in the emergency department is substantial in the United States. J Health Econ Outcomes Res. 2017;5(1):1-15.

https://jheor.org/article/9793-cost-of-intravenous-analgesia-for-the-management…

2. HEOR Study – Cost of IV Morphine in the EU

Casamayor M, DiDonato K, Hennebert M, Brazzi L, Prosen G. Administration of intravenous morphine for acute pain in the emergency department inflicts an economic burden in Europe. Drugs Context. 2018;7:212524.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898605/

3. HEOR Study – Cost of IV PCA

Palmer P, Ji X, Stephens J. Cost of opioid intravenous patient-controlled analgesia: results from a hospital database analysis and literature assessment. Clinicoecon Outcomes Res. 2014;6:311-318.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4073913/

4. HEOR Study – A Commentary on Opioid Stewardship: Fentanyl, Sufentanil, and Perioperative Pain

Fudin J, Bettinger JJ, Dasta JF. A commentary on opioid stewardship: fentanyl, sufentanil, and perioperative pain. Pract Pain Manag. 2020;20(6).

https://www.practicalpainmanagement.com/treatments/pharmacological/opioids/comm…

This information is NOT presented to make safety or efficacy claims about our products. The intent of providing this information is to disseminate scientific literature currently available about our products. Please read each study to understand the strengths and limitations of the data.

Publications

Publications

DSUVIA®

ZALVISO®

Health Economics and Outcomes Research Articles

DSUVIA^®

ZALVISO^®